Diagnostic and prognostic biomarker discovery strategies for autoimmune disorders

Current clinical, laboratory or radiological parameters cannot accurately diagnose or predict disease outcomes in a range of autoimmune disorders. Biomarkers which can diagnose at an earlier time point, predict outcome or help guide therapeutic strategies in autoimmune diseases could improve clinica...

Full description

Saved in:
Bibliographic Details
Published in:Journal of proteomics 2010-04, Vol.73 (6), p.1045-1060
Main Authors: Gibson, David S., Banha, Joao, Penque, Deborah, Costa, Luciana, Conrads, Thomas P., Cahill, Dolores J., O'Brien, John K., Rooney, Madeleine E.
Format: Article
Language:English
Subjects:
Autoimmune disease
Autoimmune diseases
Behçets disease
biomarkers
Dilated cardiomyopathy
Inflammation
Juvenile idiopathic arthritis
Proteomics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current clinical, laboratory or radiological parameters cannot accurately diagnose or predict disease outcomes in a range of autoimmune disorders. Biomarkers which can diagnose at an earlier time point, predict outcome or help guide therapeutic strategies in autoimmune diseases could improve clinical management of this broad group of debilitating disorders. Additionally, there is a growing need for a deeper understanding of multi-factorial autoimmune disorders. Proteomic platforms offering a multiplex approach are more likely to reflect the complexity of autoimmune disease processes. Findings from proteomic based studies of three distinct autoimmune diseases are presented and strategies compared. It is the authors' view that such approaches are likely to be fruitful in the movement of autoimmune disease treatment away from reactive decisions and towards a preventative stand point. This review describes a number of proteomic strategies to discover biomarkers which could help to manage autoimmune disease activity by: (i) autoantibody screening, (ii) providing an earlier diagnosis, (iii) stratifying patients based on likely outcome and (iv) gauging therapeutic response. [Display omitted]
ISSN:1874-3919
DOI:10.1016/j.jprot.2009.11.013